GEN Exclusives

More »

GEN News Highlights

More »
Mar 27, 2014

MAB Discovery to Produce Antibodies for Genmab

  • Munich, Germany-based company MAB Discovery has cut a deal with Genmab and its affiliate Genmab BV, under which it will produce antibodies for multiple Genmab targets to help Genmab and Genmab BV develop their therapeutic antibody products.

    To generate the antibodies, MAB Discovery will be using its in vivo antibody discovery technology platform, which the company says relies on the natural immune response of rabbits followed by B-cell cloning techniques. MAB Discovery uses high-throughput screening to focus on identifying highly active antibodies with epitope coverage, potency, and species-cross-reactivity. This technology, the firm adds, can eliminate affinity maturation and surrogate development.

    MAB Discovery's CEO Stephan Fischer, Ph.D., said in a statement that the firm is thrilled to provide its rabbit-based in vivo platform to Genmab. "Genmab’s antibody format technologies, the DuoBody and HexaBody platforms, combined with our antibody discovery platform could lead to the discovery of best-in-class therapeutic antibodies," he added. 

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »